My clinical and research interests include: (1) molecular diagnostics in lung cancer, (2) managing acquired resistance to targeted therapies (such as ALK, EGFR, ROS1 tyrosine kinase inhibitors), and (3) developing rational combinations of therapies based on evolutionary and molecular biology. I am also interested in novel clinical trials that address unmet needs among our patients with lung cancer.

Care Philosophy

I believe that there is no "one-size fits all" approach in medicine, especially with cancer therapy. I strive to use the best scientific principles available and tailor these to the individual needs and circumstances of each patient.

Specialties

Hematology and Oncology ( 2020 )
Internal Medicine ( 2016 )

Conditions & Treatments

Cancers
Cancer Medicine, Lung Cancer

Interests & Activities

Personal Interests

I am interested in targeted therapies and novel biomarkers. My true passion outside of medicine is classical piano performance. I also dabble with sketch comedy, film, and skiing on the side.

Education & Training

Medical Schools

MD, Keck School of Medicine of the University of Southern California (2013)

Undergraduate Schools

BA, University of Pennsylvania (Philadelphia, PA) (2007)

Internships

University of Colorado (2013)

Residency Program

University of Colorado (2016)

Fellowships

University of Colorado (2020)

Professional Memberships

American Association of Cancer Research (AACR), Member

American Society of Clinical Oncology (ASCO), Member

European Society for Clinical Oncology (ESMO), Member

International Association for the Study of Lung Cancer (IASLC), Member

National Comprehensive Cancer Network (NCCN), Voting Member

Rocky Mountain Oncology Society, President

SWOG Cancer Research Network, Lung Steering Committee

Research & Grants

Grants

Patterns of relapse in stage III NSCLC treated with curative intent and the utility of serum tumors markers in the surveillance setting (2019)

Personalized medicine models and linked electronic database to assess racial and socioeconomic disparities among patients with lung cancer in Colorado (2020)

Programmed death ligand 1 (PD-L1) expression as a biomarker for tyrosine kinase inhibitor (TKI) efficacy among patients with ALK-rearranged NSCLC (2022)

MET and EGFR as biomarkers for amivantamab in overcoming RET TKI resistance (2022)

Characterizing MET receptor tyrosine kinase adaptations of drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors (2023)

Using spatial multi-omics to characterize receptor tyrosine kinase adaptations in drug-tolerant persister cells (2023)

Paul Calabresi Clinical Oncology Scholar (2024)

Cell cycling adaptations in drug-tolerant persister cells in non-small cell lung cancer treated with tyrosine kinase inhibitors (2024)

Research Interests for Patients

My research interests are in precision oncology, biomarker testing and development, targeted therapies, and characterizing acquired resistance to cancer therapies.

information for referring providers

Referral Contact Phone

720-848-0300

Clinical Interests for Referring Providers

Research Interest for Referring Providers

My translational research interests in lung cancer focus on three main themes: (1) leveraging molecular testing to identify prognostic and potentially predictive biomarkers to guide sequencing of anti-cancer therapies, (2) understanding the mechanisms of acquired resistance to targeted therapies, and (3) using evolutionary principles to develop rational anticancer therapy combinations to eradicate cancer persistence.

Find A Provider

Practice Locations

UCHealth Lung Cancer Clinic - Anschutz Medical Campus

Tejas Patil, MD

Hematology and Oncology

Position Name

Gender

Department

Specialty

Primary Clinic Phone

Hospital Affiliations

Locations